Search

Savara Inc

Ouvert

SecteurSoins de santé

5.6 0.18

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.51

Max

5.64

Chiffres clés

By Trading Economics

Revenu

-2.9M

-40M

BPA

-0.16

Employés

70

EBITDA

-3M

-40M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+99.46% upside

Dividendes

By Acuity

Prochains Résultats

10 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-32M

1.1B

Ouverture précédente

5.42

Clôture précédente

5.6

Sentiment de l'Actualité

By Acuity

48%

52%

162 / 340 Classement par Healthcare

Savara Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 août 2026, 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

24 août 2026, 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

21 août 2026, 19:36 UTC

News

Savara Inc. granted inducement awards to eight new employees, including options for 74,500 shares. Shares are higher since Thursday's close.

20 août 2026, 20:02 UTC

Savara Inc shares are lower amid a broader market downturn, influenced by disappointing sales growth from major retailers like Walmart Inc. Trading volume remains unusually high.

19 août 2026, 19:26 UTC

Savara Inc is trading higher today, maintaining upward momentum since Tuesday's close. The stock moved from a session low to a pre-market high.

18 août 2026, 23:01 UTC

Savara Inc shares declined in after-market trading, falling below their 20-day moving average after an earlier surge. No specific news was identified to explain the volatility.

17 août 2026, 19:46 UTC

Savara Inc is trading lower today, retracing from earlier gains and near the lower end of its one-month range. No specific news was identified.

14 août 2026, 19:44 UTC

Savara Inc shares are higher today amid increased trading volume. No specific company news was identified to explain the price movement.

13 août 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Wednesday. The stock saw high trading volume amid no specific news.

12 août 2026, 19:56 UTC

News

Savara Inc. shares are higher following Citizens' reaffirmation of its Outperform rating and $10 price target ahead of the MOLBREEVI PDUFA date.

11 août 2026, 19:11 UTC

Savara Inc shares are lower today amid unusually high market volume. No specific news was identified to explain the decline.

10 août 2026, 23:01 UTC

Savara Inc shares are lower in after-market trading, showing notable volatility without any specific news to explain the decline.

7 août 2026, 19:36 UTC

Savara Inc is trading higher, benefiting from broader market gains following a weaker-than-expected jobs report that may delay Federal Reserve interest rate hikes.

6 août 2026, 20:06 UTC

Savara Inc shares are higher today, recovering from earlier declines and trading above their 20-day moving average. No specific news was identified for the move.

5 août 2026, 19:36 UTC

News

Savara Inc. shares are higher as the company advances its Biologics License Application for molgramostim, with a key PDUFA date approaching.

4 août 2026, 23:01 UTC

Savara Inc shares are trading higher in after-market hours, showing significant volatility with no specific news identified to explain the price movement.

3 août 2026, 20:06 UTC

Savara Inc is declining today, diverging from recent higher closes. Broader market indices, including the S&P 500 and Nasdaq 100, are gaining.

31 juil. 2026, 20:06 UTC

Event

Savara Inc shares are lower despite the European Patent Office granting a patent for MOLBREEVI, effective through March 2041. The stock remains near its one-month low.

30 juil. 2026, 20:09 UTC

Event

Savara Inc shares rise after the European Patent Office grants a patent for MOLBREEVI, providing protection until March 2041.

29 juil. 2026, 19:47 UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

28 juil. 2026, 19:16 UTC

Savara Inc. shares are lower today amid ongoing price weakness. Broader markets like the FTSE 100 and DAX are showing resilience despite this decline.

27 juil. 2026, 14:02 UTC

Savara Inc shares are higher during Monday's session, reaching their peak at 9:30 AM ET. No specific news was identified to explain the movement.

24 juil. 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Thursday amid high market volume. Broader market sentiment is affected by recent oil price volatility.

21 juil. 2026, 17:41 UTC

Savara Inc. shares are advancing today amid strong trading volume. The broader market is also positive, led by gains in technology stocks.

20 juil. 2026, 20:06 UTC

Savara Inc shares are higher, continuing their advance from Friday's close. Broader market sentiment remains mixed amid ongoing geopolitical concerns.

Comparaison

Variation de prix

Savara Inc prévision

Objectif de Prix

By TipRanks

99.46% hausse

Prévisions sur 12 Mois

Moyen 11.17 USD  99.46%

Haut 16 USD

Bas 9 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

162 / 340Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat